Table 5.
Crude and adjusted ORs for the association between the risk of ILD development and variables in patients with systemic sclerosis and dermatomyositis/polymyositis
| Variable | Systemic sclerosis | Dermatomyositis/ polymyositis | ||
| Univariable | Multivariable | Univariable | Multivariable | |
| OR (95% CI) | aOR (95% CI) | OR (95% CI) | aOR (95% CI) | |
| Comorbidity | ||||
| CCI without pulmonary disease | 0.39 (0.11 to 1.46) | 5.51 (1.11 to 27.26)* | 1.55 (0.68 to 3.54) | |
| COPD | 0.80 (0.33 to 1.91) | 2.80 (0.97 to 8.07) | 4.19 (1.38 to 12.71) | 6.73 (1.39 to 32.51)* |
| Urbanisation | ||||
| Level 1 | Reference | Reference | Reference | |
| Level 2 | 1.02 (0.47 to 2.20) | 1.53 (0.56 to 4.18) | 0.90 (0.39 to 2.08) | |
| Level 3 | 0.39 (0.11 to 1.46) | 0.73 (0.15 to 3.68) | 0.74 (0.26 to 2.13) | |
| Level 4 | 0.80 (0.33 to 1.91) | 1.97 (0.51 to 7.57) | 0.84 (0.31 to 2.27) | |
| Payroll-related insured amount, New Taiwan Dollars | ||||
| ≤15 840 | Reference | Reference | Reference | |
| 15 841–28 800 | 1.01 (0.36 to 2.79) | 0.36 (0.12 to 1.11) | 0.39 (0.09 to 1.61) | |
| 28 801–45 800 | 1.19 (0.45 to 3.12) | 0.66 (0.25 to 1.77) | 0.32 (0.09 to 1.16) | |
| ≥45 801 | 1.14 (0.42 to 3.14) | 0.74 (0.30 to 1.86) | 0.24 (0.06 to 0.94)* | |
| Medication | ||||
| Methotrexate | 1.00 (0.24 to 4.11) | 5.70 (2.74 to 11.88) | 7.55 (2.77 to 20.62)** | |
| Sulfasalazine | <0.01 <0.01–>99) | 12.00 (1.25 to 115.36) | 2.31 (0.14 to 36.92) | |
| Leflunomide | 2.00 (0.18 to 22.06) | >99(<0.01–>99) | ||
| Hydroxychloroquine | 0.87 (0.44 to 1.72) | 2.21 (1.12 to 4.39) | 0.95 (0.38 to 2.38) | |
| Immunosuppressants | 2.11 (1.01 to 4.44) | 1.05 (0.40 to 2.74) | 1.52 (0.79 to 2.95) | |
| Steroid†, mg/day | 1.16 (1.07 to 1.25) | 1.12 (1.02 to 1.23)* | 1.07 (1.02 to 1.11) | 1.06 (1.004 to 1.12)* |
| Air pollutants | ||||
| PM2.5 (per 10 µg/m3) | 0.69 (0.41 to 1.18) | 1.14 (0.27 to 4.73) | 0.57 (0.34 to 0.95) | 0.31 (0.05 to 1.80) |
| PM10 (per 10 µg/m3) | 0.77 (0.57 to 1.04) | 0.91 (0.35 to 2.35) | 0.72 (0.54 to 0.97) | 1.34 (0.47 to 3.79) |
| SO2 (per 10 ppb) | 0.06 (0.00 to 2.27) | 0.12 (<0.01 to 16.34) | 0.07 (0.00 to 1.99) | 2.82 (0.01 to 574.01) |
| NO2 (per 10 ppb) | 0.95 (0.53 to 1.70) | 0.90 (0.50 to 1.62) | ||
| CO (per 1 ppm) | 0.96 (0.24 to 3.86) | 0.51 (0.11 to 2.43) | ||
| O3 (per 10 ppb) | 0.28 (0.08 to 1.02) | 0.16 (0.02 to 1.30) | 0.30 (0.08 to 1.11) | 0.36 (0.06 to 2.40) |
*p<0.05, **p<0.005.
†Prednisolone equivalent.
CCI, Charlson comorbidity index; CO, carbon monoxide; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; NA, not available; NO2, nitrogen dioxide; O3, ozone; PM10, particulate matter <10 μm; PM2.5, particulate matter <2.5 μm; SO2, sulphur dioxide; TNF, tumour necrosis factor.